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ABSTRACT
B-chronic lymphocytic leukemia (B-CLL) patients harboring p53 mutations 
are invariably refractory to therapies based on purine analogues and have limited 
treatment options and poor survival. Having recently demonstrated that the 
mitochondria-targeting small molecule sodium dichloroacetate (DCA) exhibits anti-
leukemic activity in p53wild-type B-CLL cells, the aim of this study was to evaluate the 
effect of DCA in p53mutated B-CLL cells and in p53mutated/null leukemic cell lines. DCA 
exhibited comparable cytotoxicity in p53wild-type and p53mutated B-CLL patient cell cultures, 
as well as in p53mutated B leukemic cell lines (MAVER, MEC-1, MEC-2). At the molecular 
level, DCA promoted the transcriptional induction of p21 in all leukemic cell types 
investigated, including p53null HL-60. By using a proteomic approach, we demonstrated 
that DCA up-regulated the ILF3 transcription factor, which is a known regulator of 
p21 expression. The role of the ILF3/p21 axis in mediating the DCA anti-leukemic 
activity was underscored by knocking-down experiments. Indeed, transfection with 
ILF3 and p21 siRNAs significantly decreased both the DCA-induced p21 expression and 
the DCA-mediated cytotoxicity. Taken together, our results emphasize that DCA is a 
small molecule that merits further evaluation as a therapeutic agent also for p53mutated 
leukemic cells, by acting through the induction of a p53-independent pathway.
INTRODUCTION
Emerging data indicate that cancer associated 
oxidative stress, resulting from the accumulation of 
reactive oxygen species and leading to genetic instability 
and drug resistance [1,2], might be involved in the 
pathogenesis of B-chronic lymphocytic leukemia (B-CLL) 
[3]. A recent study has demonstrated the prevalence 
of oxidative stress in B-CLL patients, adaptation to 
permanent intrinsic oxidative stress and mitochondrial 
biogenesis [4]. Thus, the mitochondria might be primary 
targets of cancer therapeutics instead of simple bystanders 
during cancer development. In this context, there is an 
increasing interest for the therapeutic potentiality of the 
mitochondria-targeting dichloroacetate (DCA) against 
malignant cells. Indeed, preclinical studies confirm the 
relatively low toxicity of DCA and document its efficacy 
against numerous epithelial cancers (such as non-small 
cell lung, endometrial, prostate, breast and colorectal 
cancer), glioblastoma, as well as multiple myeloma 
[5-14]. Recently, we have demonstrated that DCA is 
cytotoxic also in p53wild-type primary B-CLL patient cells 
and in p53wild-type B leukemic cell lines [15], when used in 
the same range of concentrations previously employed in 
in vitro studies performed in solid tumors and multiple 
myeloma cells [10-12,14]. Moreover, we found that in 
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p53wild-type B leukemic cells DCA activates p53 and potently 
synergizes with Nutlin-3, a non-genotoxic activator of the 
p53 pathway [15].
Although these findings were promising, a major 
unresolved clinical problem of B-CLL is represented 
by the lack of effective treatments for B-CLL patients 
harboring TP53 mutations [16]. In this respect, although 
TP53 mutations in naïve B-CLL were usually considered 
a rare (<5%) event [16-17], a recent study performed using 
the next generation sequencing technology demonstrated 
that very small TP53 mutated subclones are present in 
9% (28/309) of newly diagnosed B-CLL patients [18], a 
percentage significantly higher than previously reported 
by the Sanger technology. Of note, patients harboring 
small TP53 mutated subclones showed the same clinical 
phenotype and poor survival as patients carrying clonal 
TP53 lesions [18]. In addition, the percentage of TP53 
mutations dramatically increases up to >30% after 
relapsed chemotherapy [19].
On these bases, the aim of the present study was 
to evaluate the potential therapeutic activity of DCA 
in p53mutated B leukemic cells. For this purpose, DCA 
cytotoxicity was evaluated on primary p53mutated B-CLL 
patient cells in comparison with p53wild-type B-CLL patient 
cells as well as on a panel of p53mutated B leukemic cell 
lines (MAVER, MEC-1, MEC-2). Finally, in order to 
dissect the p53-independent molecular mechanisms of 
DCA cytotoxicity, a set of experiments was performed 
using the p53null HL-60 leukemic cell line. 
RESULTS
DCA promotes comparable cytotoxicity in p53wild-
type and p53mutated B-CLL patient cells 
Since B-CLL patients characterized by p53 
dysfunction have limited treatment options and poor 
overall survival [16,18,19], in the first set of experiments 
we comparatively evaluated the in vitro effect of DCA 
assessed on B-CLL patient cells characterized by either 
p53 wild-type or harboring TP53 mutations (Table 1). For 
this purpose, upon validation of a TP53 next generation 
sequencing screening (performed on a total of 80 B-CLL 
patients), we selected 5 patients with p53 wild-type 
and 5 patients characterized by mutations potentially 
affecting p53 functionality, as predicted by web mutation 
pathogenicity prediction tools and protein structural 
bioinformatic analysis (Table 1 and Supplementary Figure 
1). B-CLL cell cultures were exposed in vitro to DCA in 
a range of concentrations (1-30 mM) previously used by 
other authors in in vitro solid tumor models [10-12,14], 
and in our recent study performed in primary p53wild-
type B-CLL cells [15]. As documented by the IC50 (50% 
inhibition concentration) values, in vitro treatment with 
DCA induced a significant and progressive reduction 
of cell viability, with respect to the untreated cultures 
assessed at the same time points (24 and 48 hours), in all 
the primary B-CLL patient cell cultures, irrespectively of 
the p53 status (Table 2). 
Although we have previously shown that DCA 
Figure 1: Cytotoxicity induced by DCA in p53mutated/null leukemic cell lines. The p53mutated B leukemic cell lines MAVER, MEC-
1 and MEC-2 (A), as well as the p53null HL-60 cells (B), were exposed to serial doses of DCA (range 1-30 mM) before analysis of cell 
viability at both 24 and 48 hours of treatment. Dose response curves were derived by calculating the cell viability as percentage with respect 
to the untreated cultures (set to 100%). Data are means±SD of at least three independent experiments, each performed in duplicate (Mann-
Whitney rank-sum test; asterisks, p<0.05).
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Table 1: Clinical and laboratory characteristics of the B-CLL patients
B-CLL 
Pt.# Sex Age
Rai 
stage Therapy
%CD38+ 
cells %ZAP-70+
Cytogenetic 
Abnormalities*
IgVH 
status TP53 analysis (NGS)
1 M 73 0 none 10.3 10.2 del13q mut unmut
2 F 78 0 F 6.3 1.8 del11q/del13q omoz. unmut unmut
3 M 63 0 FCR 0 24.3 del13q unmut unmut
4 M 54 II FCR 1.2 60 normal unmut unmut
5 M 77 IV Chl 15.4 72.1 tris 12 unmut unmut
6 M 55 0 FCR 6.7 18.9 tris 12 unmut NM_000546:exon5:c.470T>A:p.V157D
7 M 71 IV FCR 6.5 na del13q/del17p mut
NM_000546:exon8:c.817C>T:p.
R273C
NM_000546:exon7:c.701A>G:p.
Y234C 
8 M 68 IV R-Benda 16.6 8.6 del11q/del13q/del17p unmut
NM_000546:exon7:c.770T>C:p.
L257P
9 M 79 II Chl 14.3 1.9 del13q/del17p unmut NM_000546:exon6:c.376-2A>G: p.Y126Tfs*44
10 M 75 0 Chl 3.6 41.1 del13q/del17p na NM_000546:exon8:c.832C>T:p.P278S
Pt., patient; NGS, next generation sequencing; mut, mutated; unmut, unmutated; na, not available; F, Fludarabine; FCR, 
Fludarabine-Cyclophosphamide-Rituximab; R-Benda, Rituximab-Bendamustine; Chl, Chlorambucil. * Cytogenetic 
abnormalities were evaluated by fluorescence in situ hybridization (FISH) analysis.
Table 2: IC50 for DCA in leukemic cells
Leukemic cells TP53 status 
IC50 DCA (mM)
24 hours 48 hours
B-CLL Pt.#1 wild-type 20.6 14.7
B-CLL Pt.#2 wild-type 24.8 12.7
B-CLL Pt.#3 wild-type 28.5 9.7
B-CLL Pt.#4 wild-type 23.1 16.5
B-CLL Pt.#5 wild-type 36.2 <1
B-CLL Pt.#6 mutated 41.9 20.4
B-CLL Pt.#7 mutated 32.1 15.0
B-CLL Pt.#8 mutated 5.0 <1
B-CLL Pt.#9 mutated 17.0 15.6
B-CLL Pt.#10 mutated 28.1 14.8
MAVER mutated 27.9 14.5
MEC-1 mutated 16.2 10.4
MEC-2 mutated 33.7 22.7
HL-60 null 43.0 24.4
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Figure 2: Effects of DCA treatment on p53mutated/null leukemic cell lines. The p53mutated B leukemic cell lines MAVER, MEC-1 and 
MEC-2, as well as the p53null HL-60 cells, were exposed to DCA (30 mM). In A, cell distribution in the different phases of the cell cycle was 
calculated from the flow cytometry dot plots after BrdU/PI staining and expressed as percentage of the total population. In the upper panel, 
data are reported as the means of results from at least three independent experiments (Mann-Whitney rank-sum test; asterisks, p<0.05). 
In the lower panel, representative cell cycle profiles of cultures, either left untreated or treated with DCA, analyzed by flow cytometry 
are shown. For each cytofluorimetric analysis, the rectangles represent the cells in G0/G1, S, G2/M phases of the cell cycle. In B, cell 
senescence was visualized by SA-β-gal staining. Representative fields observed under light microscope are shown (arrows, senescent cells); 
cells with positive staining for SA-β-gal were quantified by counting a total of 1000 cells for each culture condition. Data are expressed as 
means±SD of six different fields in three independent experiments (Mann-Whitney rank-sum test; asterisks, p<0.05). In C, assessment of 
mitochondrial alterations was carried out by morphological and functional analyses. Transmission electron microscopy images of cytosolic 
regions show mitochondria (asterisks; original magnification 31,500X) with either normal morphology or cristae remodeling, in untreated 
or DCA treated cultures, respectively. Representative fields of three independent experiments are shown. In the lower panel, cellular ATP 
levels were quantified in cell lysates at the indicated time points. Data are reported as percentage with respect to the untreated cultures 
(set to 100%) and are means±SD of three independent experiments, each performed in duplicate (Mann-Whitney rank-sum test; asterisks, 
p<0.05). In D, the percentage of apoptotic cells was determined by flow cytometry after Annexin V/PI staining. Representative experiments 
are shown. In the graph, data are reported as the means±SD of results from at least three independent experiments (Mann-Whitney rank-
sum test; asterisks, p<0.05). 
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activates the p53 pathway in p53wild-type B leukemic cells 
[15], the current set of data suggested that DCA can 
promote cytotoxicity also independently of functional p53. 
Thus, to investigate the molecular mechanisms underlining 
DCA cytotoxicity in leukemic cells with dysfunctional 
p53, we selected three p53mutated B leukemic cell lines 
(MAVER, MEC-1, MEC-2), which exhibited a dose- 
and time-dependent cytotoxic response to DCA (Figure 
1A) with IC50 values comparable to those assessed for 
primary p53wild-type and p53mutated B-CLL cells (Table 2). The 
ability of DCA to promote p53-independent cytotoxicity 
in leukemic cells was further supported by experiments 
performed on the p53null HL-60 cell line (Figure 1B). The 
cytotoxicity induced by DCA in p53mutated/null leukemic 
cell lines was the result of (i) a cytostatic effect with the 
accumulation in G1 phase of the cell cycle (Figure 2A), 
(ii) the promotion of cellular senescence (Figure 2B), 
(iii) the induction of mitochondrial damage (Figure 2C), 
coupled to (iv) apoptosis (Figure 2D).
DCA induces the transcription of p21 in both 
p53wild-type and p53mutated/null leukemic cells
In the next set of experiments, we have investigated 
the mRNA levels of p21, whose in vitro induction 
represents a positive prognostic marker of response to 
therapy [20]. Surprisingly, DCA was equally effective in 
increasing the transcription levels of p21 in both primary 
p53wild-type and p53mutated B-CLL leukemic cells (Figure 3A). 
The induction of p21 was confirmed at the protein level 
by Western blot analysis. Moreover, DCA significantly 
increased the steady-state mRNA levels in all the p53mutated 
B cell lines (MAVER, MEC-1 and MEC-2) as well as in 
p53null HL-60 (Figure 3A), thus confirming the ability 
of DCA to induce p21 expression independently of the 
presence of p53. In parallel, a confirmation of the lack 
of functional p53 transcriptional activity in both p53mutated 
primary B-CLL cells and p53mutated MAVER, MEC-1 and 
MEC-2 cell lines as well as in p53null HL-60 was provided 
Figure 3: Induction of p21 by DCA in p53mutated/null leukemic cells. Levels of p21 were analyzed by quantitative RT-PCR in the 
p53wilde-type and p53mutated B-CLL patient samples, as well as in the p53mutated B leukemic cell lines (MAVER, MEC-1 and MEC-2) and in the 
p53null HL-60 cells. In A, levels of p21 modulation upon 24 hours of treatment with DCA (30 mM) are shown. Representative western blot 
results documenting induction of p21 protein by DCA in 2 B-CLL patient samples are shown in the insets. In B, the same cell cultures were 
exposed for 24 hours to Nutlin-3 (10 µM) before measurement of p21 levels. In parallel, as a positive control, p21 induction by Nutlin-3 was 
assessed in a p53wild-type B-CLL sample. In A and B, mRNA levels are expressed as fold of modulation with respect to the control untreated 
cultures set at 1. Results are reported as means±SD of at least three independent experiments, performed in duplicate, carried out on each 
leukemic sample.
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by the use of Nutlin-3, a small molecule activator of p53 
[21]. Indeed, while Nutlin-3 (10 µM) potently induced 
p21 transcription in primary p53wild-type B-CLL cells, it 
did not promote any modulation of p21 mRNA over the 
baseline in both primary p53mutated B-CLL patient samples 
and p53mutated/null leukemic cell lines (Figure 3B), thus 
confirming the p53-independent activation of p21 by DCA 
in these cell models. 
Role of ILF3-p21 axis in DCA induced cytotoxicity 
To gain insight into the p53-independent induction 
of p21 by DCA, we adopted a proteomic approach using 
the HL-60 p53null leukemic model in order to rule out 
any potential interference by mutated p53 protein. For 
this purpose, we used a 1-DE gel approach for protein 
pre-fractionation integrated into a typical LC-MS/
MS workflow for protein identification, performed as 
previously described [22]. A label-free approach (spectral 
counting) was then used for relative protein abundance 
quantification. Overall, our proteomic analysis identified 
727 proteins in the total lysate of untreated and DCA 
treated HL-60 cells. According to statistical tests, HL-
60 exposed to DCA for 24 hours exhibited a significant 
difference (at least 3-fold) in the abundance of 17 
proteins compared to the untreated counterpart, with 
10 up-regulated proteins and 7 down-regulated proteins 
(Supplementary Tables 1 and 2). Network analysis, using 
MetaCore bioinformatic tools of the 17 significantly 
deregulated proteins, revealed the involvement of Cellular 
metabolic processes as the main GO processes altered by 
DCA treatment (Figure 4A). In addition, when MetaCore 
software was used to map the shortest paths of interactions 
among the differentially expressed proteins, 12 out of 
17 proteins were brought together with p21 as the hub 
of the identified network (Figure 4B). Interestingly p21 
was directly connected with interleukin enhancer-binding 
factor 3 (ILF3, also known as NFAT-90).
On the base of the proteomic results, we next 
tested the potential role of p21 in mediating the anti-
leukemic activity of DCA using again the p53null HL-60 
cells as model system, by utilizing siRNAs to attenuate 
p21 expression. As shown in Figure 4C, once confirmed 
the effective knock-down of p21 expression through 
quantitative RT-PCR both at baseline and after DCA 
treatment, we observed a significant (p<0.05) reduction in 
DCA-induced cytotoxicity in p21 siRNA transfected cells 
with respect to cells transfected with a scrambled control 
siRNA. Concurrently, p21 silencing reversed the cell cycle 
arrest, as documented by the minor extent in cell blockage 
in S phase upon DCA treatment (data not shown). This set 
of data confirmed that p21 plays a central role in mediating 
cytotoxicity of DCA not only in p53wild-type B leukemic cells 
[15] but also in p53deficient leukemic cells.
Subsequently, in order to disclose the mechanism 
of p21 regulation by DCA, we attenuate ILF3 
expression. As shown in Figure 4D, the knock-down 
of ILF3 expression by siRNA transfection determined 
the concomitant reduction in p21 mRNA levels both in 
untreated culture and upon DCA exposure, consistently 
with the documented role of ILF3 as a regulator of p21 at 
transcriptional and post-transcriptional levels [23,24] as 
summarized in Supplementary Figure 2. The involvement 
of ILF3 in DCA anti-leukemic signaling pathway, in 
absence of functional p53 pathway, was revealed by 
the effect of its down-modulation in attenuating DCA 
cytotoxicity, similarly to the effect resulted by p21 gene 
silencing (Figure 4D-E). On the other hand, knock-down 
of ILF3 expression in p53wilde-type cells did not determine 
significant modulatory effects on p21 (both in untreated 
culture and upon DCA exposure; Supplementary Figure 
3). Although this is not a direct evidence of the role of p53 
in p21 regulation, nevertheless it suggests a prominent role 
of p53-pathway in the p21 induction by DCA in p53wild-type 
cells.
DISCUSSION
Agents directed against the unique metabolic 
features of cancer cells might represent an opportunity 
to improve current treatments, in particular with the 
aim of overcoming drug resistance in leukemic cells. 
In this context, we have recently demonstrated that the 
mitochondria-targeting small molecule DCA promoted 
cytotoxicity in p53wild-type primary B-CLL cells and B 
leukemic cell lines at concentrations which marginally 
affected primary normal peripheral blood mononuclear 
cells [15]. However, p53 mutations are known to interfere 
with the normal response of human cells to oxidative 
stress. The failure of p53 mutant-expressing cells to restore 
a reducing oxidative environment is often accompanied by 
increased survival [25], which represents an aspect of the 
gain of function of the pro-oncogenic activity of mutated 
TP53. Thus, it remained to be established whether DCA 
was active also on p53mutated leukemic cells.
In this study, we have demonstrated for the first 
time that DCA exerts cytotoxic activity in both primary 
p53mutated B-CLL cells and p53mutated/null leukemic cell lines, 
at levels comparable to primary p53wild-type B-CLL cells, 
in a range of concentrations previously used by other 
authors in in vitro models of solid tumors [10-12,14]. 
These findings are particularly remarkable since patients 
harboring TP53 mutations have a poor prognosis and still 
limited therapeutic options [18]. In addition, we have 
demonstrated that DCA induces cell cycle arrest in the G1 
phase, senescence, apoptosis, also independently of p53. 
Moreover, although it has been previously hypothesized 
that the lack of mitochondrial hyperpolarization in 
hematological malignancies might render DCA ineffective 
in such cases [26], DCA efficiently induced mitochondrial 
damage in all p53mutated/null leukemic cell lines investigated. 
Indeed, we documented both the morphological 
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Figure 4: Role of p21 and ILF3 pathway in mediating the anti-leukemic activity of DCA in p53null leukemic cells. In A-B, 
proteomic profiling in HL-60 cells upon DCA treatment revealed significant different (at least 3 folds) levels for 17 proteins in DCA treated 
cultures compared to the untreated cells (Supplementary Table 2). In A, the top ten GO processes, prioritized in according to p-value, in 
response to DCA treatment is shown. In B, the protein network generated by the shortest path algorithm using the list of the differently 
expressed proteins (more than 3 fold induction/reduction) is reported. Nodes represent proteins and the different shapes of the nodes 
represent the functional class of the proteins. Circles evidence protein identified in our proteomic analysis. Lines connecting the nodes 
indicate indirect interactions (activation, induction, modification) or direct binding; the arrowheads indicate the direction of the interaction. 
Blue broken line circles highlight network hubs as indicated by network statistics. In C-D, HL-60 cells were transfected with either control 
scrambled (scr) siRNA, or p21 siRNA (C) or ILF3 siRNA (D) before treatment with DCA (30 mM). After transfection, levels of p21 mRNA 
were analyzed by quantitative RT-PCR (C-D). Data are expressed as arbitrary units (a.u.). In parallel transfected cultures were analyzed for 
cell viability upon exposure to DCA; results are expressed as percentage of viable cells with respect to the control cultures (set to 100%). 
Data are reported as means±SD of results from three independent experiments, each performed in duplicate (Mann-Whitney rank-sum test; 
asterisk, p<0.05). In E, a schematic representation of the potential p53-independent pathway mediating the anti-leukemic activity of DCA 
is shown. 
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remodeling of mitochondrial structure and the reduction 
in ATP synthesis. Consistently, also the proteomic 
analyses revealed a relevant modulation of proteins 
involved in the metabolic processes including proteins 
of the mitochondrial inner membrane, such as adenine 
nucleotide translocase 2 (ANT2) [27] and nicotinamide 
nucleotide transhydrogenase (NNT) [28]. Overall, these 
data support the notion that DCA cytotoxity in p53mutated 
B-CLL cells is also to be ascribed to the metabolic activity 
of this compound.
Even though we have previously demonstrated 
that DCA activated the p53 pathway and promoted the 
transcription of several p53 target genes in p53wild-type B 
leukemic cells [15], we have here demonstrated that DCA 
induced the transcription of p21 also in a p53-independent 
manner in both primary p53mutated B-CLL patient cells and 
p53mutated/null leukemic cell lines. Another novel finding 
of our study was the identification of the transcription 
factor ILF3 as a key protein regulating p21 expression 
in leukemic cells and in response to exposure to DCA. 
Indeed, the knock-down of ILF3 in p53null HL-60 cells 
resulted in the attenuation of p21 expression as well as 
in the significant decrease of DCA-mediated cytotoxicity.
Recent studies confirmed that p21 is necessary 
for the induction of mitochondrial dysfunction observed 
in senescence and this event maintains a constant DNA 
damage response leading to prolonged cell cycle arrest 
[29]. P21 prevents cancer cell growth due to its ability to 
transiently or permanently stop proliferation, thus being 
an important component of tumor suppressor mechanisms. 
Indeed, it has recently been demonstrated that p21 can be 
down-regulated by several microRNA expressed in cancer 
cells [30,31]. Concurrently, although p21 levels have been 
found elevated in some cancers without signs of growth 
inhibition [32] and in some experimental settings it has 
been proposed that p21 can actually favor transformation 
by inhibiting apoptosis [31], other studies have recently 
shown that p21 can also trigger cell death [20,29]. At 
present, it is not well understood how p21 exerts these 
radically different functions or even if they reside in 
separate domains of the protein. 
In spite of the discrepancies present in the scientific 
literature, our current data clearly point to the tumor-
suppressor activity of p21 in the context of DCA-induced 
cytotoxicity on p53mutated primary B-CLL cells as well 
as on p53mutated/null leukemic cell lines. In agreement with 
our current data, it has been demonstrated that the in 
vitro activation of p21 in B-CLL accurately predicts 
the therapeutic response in vivo of B-CLL [20]. Since 
p53 mutations still represent one of the major negative 
prognosticators of B-CLL, we believe that the therapeutic 
potential of DCA should be further evaluated possibly in 
combination with other innovative anti-leukemic drugs.
METHODS
Primary B-CLL patient samples and leukemic cell 
lines 
For experiments with primary cells, peripheral 
blood samples were collected in heparin-coated tubes 
from B-CLL patients (n=10) following informed consent, 
in accordance with the Declaration of Helsinki and in 
agreement with institutional guidelines (University-
Hospital of Ferrara). The patients had been without prior 
therapy at least for three weeks before blood collection. 
Peripheral blood mononuclear cells (PBMC) were 
isolated by gradient centrifugation with lymphocyte cell 
separation medium (Cedarlane Laboratories, Hornby, ON, 
CAN). T lymphocytes, NK lymphocytes, granulocytes 
and monocytes were negatively depleted from peripheral 
blood B-CLL with immunomagnetic microbeads (MACS 
microbeads, Miltenyi Biotech, Auburn, CA), with a purity 
>95% of resulting CD19+ population, as assessed by flow 
cytometry analysis and previously described [33]. 
To analyze the TP53 status, B-CLL patients’ DNA 
samples obtained from circulating CD19+ cells were 
sequenced on Ion Torrent Personal Genome Machine 
system using a custom Ion AmpliSeq panel (Life 
Technologies, Carlsbad, CA) targeting the exonic regions 
and the exon-intron boundaries of TP53. Next generation 
sequencing data was annotated by a standard ANNOVAR 
pipeline supplied by COSMIC v68 database. All selected 
variants were validated by Sanger sequencing, first on 
genomic DNA and in case of splicing variants on cDNA. 
The potential pathogenicity of the identified mutations 
and their effects on p53 functionality was predicted by 
web tools (SIFT, http://sift.jcvi.org/; PolyPhen-2, http://
genetics.bwh.harvard.edu/pph2/; MutationTaster, http://
www.mutationtaster.org/; HSF, http://www.umd.be/HSF; 
NNSplice, http://www.fruitfly.org/seq_tools/splice.html) 
and by protein structural bioinformatics analysis (NCBI, 
http://www.ncbi.nlm.nih.gov/protein/; PDB, http://pdb.
org; UniProt, http://www.uniprot.org; PFAM, http://pfam.
sanger.ac.uk). The main clinical and molecular parameters 
of the B-CLL patients are reported in Table 1. 
For the in vitro assays, B-CLL patients’ cells were 
cultured in RPMI-1640 medium containing 10% FBS, 
L-glutamine and Penicillin/streptomycin (all from Gibco, 
Grand Island, NY) and used within the first 48 hours of 
cultures when the mean (±SD) percentage of cell viability 
was between 96.5% (±1.8%, in the first 24 hours) and 
82.5% (±7.3%, at 48 hours).
The p53mutated B lymphoblastoid leukemic cell lines 
MAVER, MEC-1 and MEC-2 and the p53null HL-60 
leukemic cell line were purchased from DSMZ (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Braunschweig, Germany). MAVER and HL-60 cell lines 
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were routinely cultured in RPMI-1640, whereas MEC-1 
and MEC-2 were maintained in IMDM, all supplemented 
with 10% FBS, L-glutamine and Penicillin/streptomycin 
(all from Gibco). Cells were then treated with DCA (range 
1-30 mM; Sigma-Aldrich, St Louis, MO), and, for selected 
experiments, with Nutlin-3 (10 µM; Cayman Chemicals, 
Ann Arbor, MI).
Analysis of DCA cytotoxicity
For the in vitro assessment of cytotoxicity, at 
different time points post DCA treatment, overall cell 
viability was examined by Trypan blue dye exclusion and 
MTT assay as previously described [34]. Apoptosis and 
cell cycle were analyzed in flow cytometry by Annexin 
V-FITC/propidium iodide (PI) staining (Immunotech, 
Marseille, France) and 5-bromodeoxyuridine (BrdU; 
Sigma-Aldrich) incorporation, respectively [35,36], 
while senescence was assessed under light microscope 
by senescence-associated β-galactosidase (SA-β-gal) 
staining, using a specific kit (Abcam, Cambridge, UK) and 
following the manufacturer’s instructions.
Assessment of mitochondrial alterations
The presence of morphological signs characteristic 
of mitochondrial alteration, such as mitochondrial 
fragmentation and cristae remodeling, were analyzed by 
transmission electron microscopy [37]. Mitochondrial 
activity was evaluated by measuring the cellular ATP 
production. Briefly, ATP concentration was determined 
using the ATP Assay KIT (Abcam) in cell lysates of 
untreated and DCA treated cultures at different time points. 
Measurements were performed with the colorimetric 
method, following the manufacturer’s instructions. ATP 
contents were normalized per number of cells.
RT-PCR and Western blot analyses
Total RNA was extracted from cells using the 
QIAGEN RNeasy Plus mini kit (QIAGEN, Hilden, 
Germany). For RT-PCR, total RNA was transcribed into 
cDNA, using the QuantiTect® Reverse Transcription kit 
(SABiosciences, QIAGEN). P21 and ILF3 gene expression 
was analyzed using the SYBR Green-based RT qPCR 
detection method with SABiosciences RT2 Real-TimeTM 
Gene expression assays, which include specific validated 
primer sets and PCR master mix (SABiosciences). All 
samples were run in triplicate using the real-time thermal 
analyzer Rotor-GeneTM 6000 (Corbett, Cambridge, UK), 
as previously described [37]. Expression values were 
normalized to the housekeeping gene POLR2A amplified 
in the same sample.
For Western blot analysis, cells were lysed as 
previously described [38]. Protein determination was 
performed by using the BCA Protein Assay (Thermo 
Scientific, Rockford, IL). Equal amounts of protein for 
each sample were migrated in SDS-polyacrylamide 
gels and blotted onto nitrocellulose filters, as previously 
described [39]. The following Abs were used: anti-p21 
(C-19) and anti-tubulin purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and from Sigma-Aldrich, 
respectively. After incubation with anti-mouse IgG 
horseradish peroxidase-conjugated secondary Abs (Sigma-
Aldrich), specific reactions were revealed with the ECL 
Lightning detection kit (Perkin Elmer, Waltham, MA) [40]. 
Densitometry values were estimated by the ImageQuant 
TL software (GE Healthcare, Buckinghamshire, UK). 
Proteomic profiling 
To perform one-dimensional gel electrophoresis 
(1-DE), for each experimental group triplicates of HL-
60 cell protein extract (25 µg/replicate) were mixed with 
equal volume of Laemmli sample buffer and resolved 
on a NuPAGE® Novex® 4-12% Bis-Tris gel (Life 
Technologies). Each gel lane was manually cut with 
a sterile surgical blade into 24 bands of equal height 
(about 3 mm) and excised bands were crushed into small 
fragments, processed, submitted to in-gel trypsin digestion 
and peptide extractions. An aliquot of each digest (2 µl) 
was directly analyzed by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) using a LTQ Orbitrap 
XL™ (Thermo Scientific), interfaced with a 1200 series 
capillary pump (Agilent Technologies Inc., Santa Clara, 
CA).
For protein identification, tandem mass spectra 
were extracted and the charge states deconvoluted by 
BioWorks version 3.3.1 (Thermo Scientific). For each 
sample, the MS/MS data from the 24 gel bands were 
merged and submitted as “mgf” file to the search engine 
Mascot (in-house version 2.2.06, Matrix Science, London, 
UK). Scaffold (version 3_00_02, Proteome Software 
Inc., Portland, ME) was used to validate MS/MS-based 
peptide and protein identifications. Mascot was set up to 
search both the forward and reversed sequences of the 
SwissProt_57.8 database (selected for Humans) assuming 
the digestion enzyme trypsin (1 missed cleavage allowed), 
mass tolerance of 1.00 Da and a parent ion tolerance of 2.0 
ppm. Carbamidomethylation of cysteine was specified as 
a fixed modification and deamidation of asparagine and 
oxidation of methionine were set as variable modifications 
in both search engines. Peptide identifications were 
accepted if they could be established at greater than 
95.0%. Protein identifications were accepted if established 
at greater than 99.9% probability with at least 2 identified 
peptides. Identified proteins were quantified using spectral 
counts directly computed by Scaffold and the number of 
MS/MS spectra were grouped into “counts” associated 
to a specific protein. Spectral counts normalization was 
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performed by Scaffold 8 version 3_00_02 (Proteome 
Software Inc.). Subsequently estimation of differential 
protein abundance was expressed as fold-change (ratio 
of the averaged spectral counts in the treated cells to 
the averaged spectral counts in the untreated cells) 
(Supplementary Table 1). The normalized spectral count 
for each identified protein were submitted to SIMCA-P13 
software package (Umetrics, Umea, Sweden) for 
multivariate data analysis (OPLS-DA). Variables that had 
significant contribution to discrimination between groups 
and a significant p-value (Mann-Whitney-Wilcoxon test, 
p<0.05), computed using JMP v6 software (SAS Institute, 
Inc., Cary, NC), were accepted as significantly modulated 
proteins upon treatment and submitted to network analysis 
(Supplementary Table 2). Functional interpretation of the 
differentially expressed proteins highlighted by proteomics 
was built using the MetaCore analytical suite version 5.3 
(GeneGo, St. Joseph, MI).
Transfection experiments
A pool of three specific small interfering RNA 
(siRNA) for each gene was resuspended in nuclease-
free sterile water. Leukemic cells (2x106 cells/0.1 ml) 
were mixed with either 1 μg of control enhanced green 
fluorescence protein (EGFP) plasmid or 3 μg of siRNA, 
transferred to a 2.0-mm electroporation cuvette and 
nucleofected with the nucleofector kit V, using the 
nucleofector device (Amaxa Nucleofector II apparatus, 
Lonza Cologne AG, Cologne, Germany), as previously 
described [41]. Transfection efficiency was monitored 
by scoring the percentage of EGFP-positive cells by flow 
cytometry analysis as previously described [42]. For p21 
and ILF3 gene knock-down, siRNAs were designed and 
manufactured by Ambion® (Life Technologies) according 
to the guidelines for effective gene knock-down by this 
method. The silencer negative control siRNA consisted 
of a 19 bp-scrambled sequence with 3’ dT overhangs and 
previously tested for the lack of non-specific effects on 
gene expression.
Statistical analysis 
Descriptive statistics were calculated. For each 
set of experiments (ie, assays for cell cytotoxicity/
functionality and RT-analysis), values were reported as 
means±standard deviation (SD). The results were analyzed 
by using the Mann-Whitney rank-sum test and statistical 
significance was defined as p<0.05. All statistical analyses 
were performed with SPSS Statistic 20 software (SPSS 
Inc., Chicago, IL). Proteomics data were analyzed by both 
multivariate and univariate approaches. The normalized 
spectral counts for each identified proteins were submitted 
to SIMCA-P13 software package (Umetrics, Umea, 
Sweden) for multivariate data analysis. Variables were 
scaled using Pareto scaling and data were analyzed by 
orthogonal partial least-squares discriminant analysis 
(OPLS-DA). S-plots were calculated to visualize the 
relationship between covariance and correlation within 
the OPLS-DA results. Variables that showed significant 
contribution to discrimination between groups and a 
significant change in their expression (Mann-Whitney-
Wilcoxon test, p<0.05), were accepted as significantly 
modulated proteins upon treatment and submitted to 
network analysis.
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